Free Trial
→ Financial legend: “This is bad, really bad...” (From Weiss Ratings) (Ad)tc pixel
NASDAQ:SCNX

Scienture Q3 2026 Earnings Date & Estimates

Scienture logo
$3.36 -0.02 (-0.59%)
Closing price 04:00 PM Eastern
Extended Trading
$3.28 -0.07 (-2.23%)
As of 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Scienture is estimated to report Q3 2026 earnings on Wednesday, November 11, 2026. The conference call is scheduled for November 13, 2026 at 4:00 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Conference Call Date
Conference Call
4:00 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Scienture in Q3 2026

Scienture is expected to post earnings of -$1.50 per share on revenue of $1.58 million. In the same quarter a year earlier Scienture reported -$4.75 per share on revenue of $0.59 million. Scienture last reported on August 13, 2026, posting -$0.07 per share and beating the -$2.25 consensus estimate. Scienture has beaten the consensus EPS estimate in 2 of its last 5 quarters.

Consensus Estimates

Consensus EPS
-$1.50
Expected Revenue
$1.58 million
Prior-Year EPS
-$4.75
Prior-Year Revenue
$0.59 million
Expected Revenue Growth
+168.5%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.07 (Beat by +$2.18)
Last Quarter Revenue
$0.34 million
EPS Beat Rate
2 of last 5 quarters

Prepare for the Q3 2026 Call

Scienture Q3 2026 Earnings FAQ

Scienture (NASDAQ:SCNX) is estimated to report Q3 2026 earnings on Wednesday, November 11, 2026. This date is estimated from past reporting schedules and may change once the company confirms it.

Scienture's Q3 2026 earnings conference call is scheduled for Friday, November 13, 2026 at 4:00 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Scienture to post earnings of -$1.50 per share for Q3 2026.

The consensus revenue estimate for Scienture is $1.58 million for Q3 2026.

Scienture Earnings Headlines

SCIENTURE Reports Approximately $1.22 Million in Unaudited Preliminary Q3 2026 Revenue, Achieving 256% Sequential Growth
October 13 at 8:05 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/13/3379660/0/en/scienture-reports-approximately-1-22-million-in-unaudited-preliminary-q3-2026-revenue-achieving-256-sequential-growth.html
Contrasting Scienture (NASDAQ:SCNX) and Silo Pharma (NASDAQ:SILO)
October 7, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31095564
Elon Musk’s 4th Wealth Window Set to Open by October 30
Jeff Brown, the analyst who flagged Bitcoin, Tesla, and Nvidia early, is tracking Elon Musk's next move. He points to a new AI project tied to Musk's Cybercab reveal. Brown says Musk has opened major investment windows before, with PayPal, Tesla, and SpaceX marking milestones in tech history. He believes a fourth may open by October 30.tc pixel
October 16 at 1:00 AM  |  Brownstone Research (Ad)
SCIENTURE Announces Arbli Added to Formularies at Three Leading U.S. Pediatric Academic Medical Centers and Hospitals
October 5, 2026  |  marketscreener.comM
Exclusive: Scienture expands institutional reach for hypertension drug with new hospital adoptions
October 2, 2026  |  msn.comhttps://www.msn.com/en-us/news/other/exclusive-scienture-expands-institutional-reach-for-hypertension-drug-with-new-hospital-adoptions/ar-AA2dpL8b
SCIENTURE Announces Arbli™ Added to Formularies at Three Leading U.S. Pediatric Academic Medical Centers and Hospitals
October 2, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/02/3373784/0/en/scienture-announces-arbli-added-to-formularies-at-three-leading-u-s-pediatric-academic-medical-centers-and-hospitals.html
See More Scienture Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Scienture? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Scienture and other key companies, straight to your email.

About Scienture

Scienture (NASDAQ:SCNX) is a specialty pharmaceutical company focused on developing and commercializing therapies for central nervous system (CNS) disorders. Its areas of interest include neurological and psychiatric conditions such as insomnia, attention-deficit/hyperactivity disorder, anxiety, depression and pain.

The company’s portfolio includes prescription pharmaceutical products and product candidates intended to provide alternative delivery methods or other potential benefits compared with existing treatments. Scienture has identified ZolpiMist, an FDA-approved oral spray formulation of zolpidem tartrate for the short-term treatment of insomnia, as part of its commercial and development portfolio.

Scienture primarily serves the U.S. pharmaceutical market and is focused on advancing, obtaining regulatory approval for, and commercializing therapies in its targeted CNS categories. The company’s operations and product strategy may evolve as it develops its pipeline and pursues commercialization opportunities.

View Scienture Profile
Earnings Tools